Abstract

COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity, or as a therapeutic, has yet been developed to SARS-CoV-2. In this study, we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competitively blocks ACE2 receptor binding, by overlapping the ACE2 structural binding epitope. Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in 293 cells expressing ACE2. When converted to secretory IgA, MAb326 also neutralizes authentic SARS-CoV-2 virus while the IgG isotype shows no neutralization. Our results suggest that SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine.

Here, Ejemel et al. report the identification and characterization of a cross-neutralizing human IgA monoclonal antibody, named MAb362, that binds the receptor-binding domain of SARS-CoV-2 Spike, blocking its interaction with the ACE2 host receptor.

Details

Title
A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction
Author
Ejemel Monir 1 ; Li, Qi 1 ; Hou Shurong 2   VIAFID ORCID Logo  ; Schiller, Zachary A 1   VIAFID ORCID Logo  ; Tree, Julia A 3 ; Wallace, Aaron 1 ; Amcheslavsky Alla 1 ; Kurt Yilmaz Nese 2 ; Buttigieg, Karen R 3 ; Elmore, Michael J 3   VIAFID ORCID Logo  ; Godwin, Kerry 3 ; Coombes, Naomi 3 ; Toomey, Jacqueline R 1 ; Schneider, Ryan 1 ; Ramchetty, Anudeep S 1 ; Close, Brianna J 4   VIAFID ORCID Logo  ; Da-Yuan, Chen 4 ; Conway, Hasahn L 4   VIAFID ORCID Logo  ; Mohsan, Saeed 4 ; Chandrashekar, Ganesa 1 ; Carroll, Miles W 3 ; Cavacini, Lisa A 1   VIAFID ORCID Logo  ; Klempner, Mark S 1 ; Schiffer, Celia A 2   VIAFID ORCID Logo  ; Wang, Yang 1   VIAFID ORCID Logo 

1  MassBiologics of the University of Massachusetts Medical School, Boston, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364) 
2  University of Massachusetts Medical School, Biochemistry and Molecular Pharmacology, Boston, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364) 
3  Public Health England, Porton Down, National Infection Service, Salisbury, UK (GRID:grid.271308.f) (ISNI:0000 0004 5909 016X) 
4  Boston University, National Emerging Infectious Diseases Laboratories, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41467-020-18058-8
ProQuest document ID
2435937443
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.